On January 4, 2021 ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, reported that management will participate in a pre-recorded presentation and host one-on-one meetings through the SternIR Virtual Corporate Access Event taking place January 11-14, 2021 (Press release, ADC Therapeutics, JAN 4, 2021, View Source [SID1234573416]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available for on-demand viewing beginning Monday, January 11, 2021, at 7:00 a.m. ET. The recording can be accessed via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com, and will be available for approximately 30 days.